Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

S068 - Therapeutic and Diagnostic Pearls

Tuesday, February 20; 10:30 AM - 12:30 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Discuss pragmatic therapeutic and diagnostic points which can be incorporated into practice
  • Describe useful, new, or evolving therapeutic interventions for skin disorders


This session will highlight important diagnostic and therapeutic pearls and is directed towards both novice and experienced clinicians. Information discussed will be based on both peer-reviewed literature and the result of personal experience.


  • Callen, Jeffrey Phillip, MD: 3M Pharmaceuticals – SH(ST); Abbott Laboratories – SH(ST); AbbVie – SH(ST); Allergan, Inc – SH(ST); Celgene – SH(ST); JAMA – B(H); Johnson and Johnson – SH(ST); Merck & Co., Inc – SH(ST); Pfizer Inc. – SH(ST); Procter & Gamble Company – SH(ST); UpToDate, Inc. – B(H);
  • Diaz, Lucia Zoraida, MD: no financial relationships exist with commercial interests.
  • Eichenfield, Lawrence F., MD: Allergan, Inc – C(H), I(Fees); Anacor Pharmaceuticals, Inc. – C(H); Cutanea Life Sciences – C(H); Dr. Reddy – C(H); DS Laboratories – C(H); Elsevier Inc. – O(IP); Galderma Laboratories, L.P. – C(H), I(Fees); Genentech, Inc. – C(H); Kimberly Clark – I(Fees); LEO Pharma, US – C(H), I(Fees); Lilly ICOS LLC – C(H); Medimetriks Pharmaceuticals, Inc. – C(H); Novan – C(H), I(Fees); Otsuka Pharmaceutical Co., Ltd. – C(H); Pfizer Inc. – C(H); Ralexar Therapeutics, Inc – C(H); Sanofi/Regeneron – C(H), I(Fees); Tioga Pharmaceuticals, Inc. – C(H); TopMD – C(SO); Valeant Pharmaceuticals International – C(H); Valeant Pharmaceuticals North America LLC – I(Fees); Wiley-Blackwell – O(H);
  • Grimes, Pearl E., MD: Allergan, Inc. – C(H), I(Grants/Research Funding); Clinuvel – I(H); Derm Tech International – I(H); Galderma Laboratories, L.P. – C(Grants/Research Funding), C(H); Incyte Corporation – I(Grants/Research Funding); Kythera – I(H); Laseroptek USA – I(Grants/Research Funding); Merz Pharmaceuticals, LLC – I(Grants/Research Funding); Obagi Medical Products – I(H); Procter & Gamble Company – C(H); Suneva Medical, Inc. – I(H); VT Technologies – I(Grants/Research Funding);
  • Hinds, Brian Robert, MD: no financial relationships exist with commercial interests.
  • Orme, Charisse Marie, MD, PhD: no financial relationships exist with commercial interests.
  • Paravar, Taraneh, MD: UpToDate, Inc – O(H);
  • Schneider, Jeremy Adam, MD: no financial relationships exist with commercial interests.
Tuesday, February 20
10:30 AM
/ Introduction
10:31 AM
Dr. Callen / Neutrophilic Dermatoses
10:45 AM
Dr. Callen / Q&A
10:47 AM
Dr. Schneider / Inpatient Consultative Dermatology and Severe Cutaneous Adverse Reactions
11:01 AM
Dr. Schneider / Q&A
11:03 AM
Dr. Hinds / The Dermatopathology Report: Pearls and Pitfalls to Maximize Clinicopathologic Correlation
11:17 AM
Dr. Schneider / Q&A
11:19 AM
Dr. Grimes / Skin of Color: Pearls of Wisdom
11:33 AM
Dr. Grimes / Q&A
11:35 AM
Dr. Paravar / Pearls in Autoimmune Skin Disease
11:49 AM
Dr. Paravar / Q&A
11:51 AM
Dr. Diaz / Pediatric Dermatology Pearls
12:05 PM
Dr. Diaz / Q&A
12:07 PM
Dr. Orme / Dermato-oncology Pearls
12:21 PM
/ Q&A
Event Details
  • Date
    Tuesday, February 20
  • Time
    10:30 AM - 12:30 PM
  • Location
    Room 6B
  • CME Credits
  • Type
  • Lawrence F. Eichenfield, MD, FAAD
  • Taraneh Paravar, MD, FAAD
  • Brian Robert Hinds, MD, FAAD
  • Charisse Marie Orme, MD, PhD, FAAD
  • Jeffrey Phillip Callen, MD, FAAD - Handout
  • Jeremy Adam Schneider, MD, FAAD - Handout
  • Lucia Zoraida Diaz, MD, FAAD
  • Pearl E. Grimes, MD, FAAD